CN112168887A - Application of Huatuo Zaizao pill in preparing medicine for treating stable fatigue type angina pectoris - Google Patents
Application of Huatuo Zaizao pill in preparing medicine for treating stable fatigue type angina pectoris Download PDFInfo
- Publication number
- CN112168887A CN112168887A CN202011165895.6A CN202011165895A CN112168887A CN 112168887 A CN112168887 A CN 112168887A CN 202011165895 A CN202011165895 A CN 202011165895A CN 112168887 A CN112168887 A CN 112168887A
- Authority
- CN
- China
- Prior art keywords
- angina pectoris
- treatment
- angina
- placebo
- huatuo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to application of Huatuo reforger pills in preparing a medicament for treating stable exertional angina. The Huatuo reproduced pill is proved to have absolute effectiveness and safety on the stable exertional angina pectoris by selecting patients with the stable exertional angina pectoris and adopting random, double-blind, placebo parallel control and multi-center clinical tests.
Description
Technical Field
The invention relates to a new application of a medicament, in particular to an application of Huatuo Zaizao pills in preparing a medicament for treating stable exertional angina.
Background
Type of angina pectoris
1. Angina pectoris of the type with respect to stability exertion
1.1 exertional angina pectoris: exertional angina is characterized by transient chest pain episodes induced by exercise or other conditions that increase myocardial oxygen demand, with the pain often disappearing rapidly after resting or sublingual nitroglycerin consumption.
Exertional angina pectoris can be classified into 3 types:
initial onset exertional angina pectoris: the disease course of exertional angina pectoris is within 1 month;
stable exertional angina pectoris: the disease course of exertional angina pectoris is stable for more than 1 month;
worsening type of exertional angina pectoris: chest pain is induced by the same degree of exertion with a sudden increase in the number, severity and duration of episodes.
1.2 spontaneous angina pectoris: spontaneous angina is characterized by an onset of chest pain that is not significantly associated with an increase in myocardial oxygen demand. This pain is generally longer lasting, more severe, and less prone to nitroglycerin relief than exertional angina.
2. For unstable angina pectoris
Initial exertional angina, worsening exertional angina and idiopathic angina are collectively referred to as "unstable angina".
Second, clinical study on placebo control
Traditional Chinese medicine has gradually gained worldwide acceptance, but the exact efficacy of the traditional Chinese medicine needs to be evaluated by scientific clinical research. Placebo control and positive drug control are important research means and techniques for clinical trials of traditional Chinese medicine, as are other clinical trial methods. However, the selection of positive control drugs in clinical studies of traditional Chinese medicine has the following problems:
1. the efficacy of many positive control drugs remains to be examined
The positive contrast medicine must be a well-known safe and effective medicine, the selected positive contrast medicine must have sufficient evidence to prove the curative effect, in fact, due to various factors such as historical conditions and imperfect legal system, varieties loaded in most pharmacopoeia or ministerial standards lack strict random, blind, contrast and multi-center clinical test research, and the effectiveness and safety of the disease treatment effect of the variety are in doubt.
2. Selection of Chinese medicine reference drug
As for the selection of the traditional Chinese medicine contrast medicine, in the Chinese patent medicines collected in pharmacopoeia or ministerial standards, the medicine which is based on the theory of traditional Chinese medicine and basically consistent with the function and the indication of the tested medicine is difficult to find, and the contrast medicine which is relatively close to the traditional Chinese medicine is selected, so that the basic principle of 'treatment by syndrome differentiation' in the traditional Chinese medicine is abandoned, the 'symptoms' are all different, and the evaluation of the symptoms of the tested medicine is difficult to reflect the effect of the medicine.
3. The disadvantage of chemical drug contrast
Although the Chinese and Western medicines are classified in the same way, the theoretical systems and treatment mechanisms of the two medicines are quite different. As is well known, western medicines have their own mechanisms and do not specifically correspond to a certain disease's symptom, and if the addendum is to be strengthened, the western medicines and the traditional Chinese medicines are simultaneously put on the aspect of improving the symptom of the disease's traditional Chinese medicine ' at the same time, and the meaning of the contrast curative effect evaluation needs to be considered.
Based on the above analysis, when it is difficult to find a reasonably effective positive control in clinical studies of traditional Chinese medicine, selecting placebo as the control becomes the most effective method and technique for clinical trials.
The placebo control can overcome the bias of researchers, subjects, and participants in evaluation due to psychological factors, etc., and can eliminate the effect of natural progression of the disease, and at the same time, the placebo control can also isolate the real adverse reactions caused by the test drugs. The placebo-controlled trial therefore reliably demonstrated the efficacy of the drug, testing absolute efficacy and safety.
In addition, randomization and blinding in the placebo-controlled trial can minimize subject and investigator bias, and can directly measure differences in efficacy and safety between the trial drug and placebo, allowing for the conclusion that the trial drug is appropriate given a smaller sample.
Huatuo reproduced pill is a Chinese medicinal compound preparation prepared from Chinese medicaments such as szechuan lovage rhizome, evodia rutaecarpa, borneol, nux vomica powder and the like, and has the effects of promoting blood circulation to remove blood stasis, promoting qi circulation to relieve pain and the like. Can be used for treating apoplexy, paralysis, spasm and numbness of limbs, facial distortion, slurred speech, etc. due to blood stasis or phlegm-dampness blocking channels and collaterals. The clinical observation in the past has proved that Huatuo Zaizao pills have certain effect on improving angina pectoris symptoms, angina pectoris curative effect, electrocardiogram curative effect and the like of patients with coronary heart disease and angina pectoris. However, the clinical designs all have the technical problems, such as lack of reasonable classification of coronary heart disease, selection of western medicines or Chinese patent medicines with pending curative effect or inconsistent functional indications as positive control medicines, and no application of randomization and blindness, so the obtained conclusion is not scientific.
Disclosure of Invention
Based on the above, the improvement effect of Huatuo Zaizao pills on the stability fatigue angina pectoris is needed to be scientifically evaluated through random, double-blind, placebo parallel control and multi-center clinical tests.
The specific technical scheme is as follows:
the invention provides application of Huatuozaizao pills in preparation of a medicine for treating stable exertional angina.
In one embodiment, the treatment is effective in treating angina pectoris of a patient.
In one embodiment, the treatment is a significant decrease in the patient's angina score.
In one embodiment, the treatment is a significant reduction in the number of angina attacks in the patient.
In one embodiment, the treatment is a significant reduction in the duration of an angina attack in the patient.
In one embodiment, the treatment is an improvement in the electrocardiogram of the patient.
In one embodiment, the treatment is a reduction of the patient's use of a nitroglycerin tablet.
Compared with the prior art, the invention has the following beneficial effects:
the Huatuo reproduced pill is proved to have absolute effectiveness and safety on the stable exertional angina pectoris by selecting patients with the stable exertional angina pectoris and adopting random, double-blind, placebo parallel control and multi-center clinical tests. The prevention and treatment effect can be shown in the effects of obviously improving the comprehensive curative effect of the Huatuo Zaizao pills on the angina pectoris of the patient, obviously reducing the angina pectoris score of the patient, obviously reducing the angina pectoris attack times of the patient, obviously reducing the angina pectoris attack duration of the patient, improving the electrocardiogram of the patient, reducing the consumption of nitroglycerin tablets for the patient and the like.
Detailed Description
The new application of Huatuo Zaizao pills of the invention is further explained in detail with reference to the specific examples. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
Examples
And (3) experimental design: randomized, double-blind, placebo-controlled, multicenter clinical trial design approach was used.
1. Clinical data
Outpatient coronary heart disease stability fatigue angina pectoris patients from the second subsidiary hospital of Tianjin Chinese medicinal university, the first subsidiary hospital of Tianjin Chinese medicinal university, and the combined medical and western medical hospital in Jilin province are randomly divided into a treatment group and a placebo group, wherein the treatment group comprises 48 patients, 5 patients are dropped, and the age is average (55.35 +/-6.85) years old; placebo group was 48 cases with 4 cases dropped and the mean age (55.33 ± 6.40) was.
Western diagnostic criteria: refer to the International society for cardiology and Association and the standardization of the world health organization clinical nomenclature Association monograph report "nomenclature and diagnostic criteria for ischemic heart disease".
The traditional Chinese medicine diagnosis standard is as follows: referring to the 2002 clinical research guidelines of new Chinese medicine for treating coronary heart disease and angina pectoris, the syndrome differentiation belongs to the syndrome of phlegm stagnation.
Inclusion criteria were: those who meet the diagnosis standard of exertional angina pectoris of stability, those who meet the diagnosis standard of exertional angina pectoris I and II; 4 weeks before the group, the angina attack per week is more than or equal to 2 times on average; the age is 35-65 years old; the standard of syndrome differentiation of phlegm stagnation and blood stasis blocking in traditional Chinese medicine is met; and (4) informed consent.
Exclusion criteria: the above inclusion criteria are met but one of the following exists: myocardial infarction for at least 3 months prior to testing; pre-infarction symptoms; angina pectoris occurs at rest; any disease that may invalidate the results of the study exists. The examination proves that the traditional Chinese medicine composition is a chest pain patient caused by coronary heart disease, acute myocardial infarction and other diseases of heart, severe neurosis, climacteric syndrome, hyperthyroidism, cervical spondylosis, cholecardia, gastric and esophageal reflux, hiatal hernia of esophagus, aortic dissection and other coronary artery diseases. Patients with hypertension complicated with hypertension and treated with antihypertensive drugs (systolic pressure is not less than 160mmHg, diastolic pressure is not less than 100mmHg), severe cardiopulmonary insufficiency, severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.), serious primary diseases of liver, kidney, hematopoietic system, etc., and psychosis patients. Patients with coronary heart disease have their blood vessels completely rebuilt within half a year after coronary bypass and interventional therapy. Allergic constitution, allergic to known medicinal components. The patients who have used the medicine with serious influence on liver and kidney functions within about 1 month. Other clinical trial participants were enrolled within the last 1 month.
2. Method of treatment
Test group (Huatuo reproduced pill group): orally taking 8g Huatuo Zaizao pill each time, 3 times per day; placebo control group: it is administered orally at a dose of 8g3 times per day. Both treatment courses were continued for 4 weeks.
The prescription of combined medication: if necessary, the sublingual nitroglycerin tablets can be used for buccal administration, and meanwhile, detailed use records are made; in addition to the test drugs and the nitroglycerin tablets, other nitrate-based preparations as well as calcium ion antagonists and beta-blockers are prohibited during the observation period, and if the patients use the preparations in the past, the preparations are stopped for at least 1 week and are taken into the lead-in period (the lead-in period can take placebo); the combination of the traditional Chinese medicine preparation for treating coronary heart disease and angina (or chest stuffiness and pains) is forbidden, if the preparation is used by a patient in the past, the medicine is stopped firstly and the preparation enters a lead-in period (at least 1 week, the placebo can be taken in the lead-in period), and the addition or dosage of the traditional Chinese medicine preparation for promoting blood circulation to remove blood stasis and reducing phlegm and dredging collaterals is forbidden during an observation period; the following drugs which have an effect on the evaluation of the curative effect of coronary heart disease angina pectoris are used: antiplatelet agents [ e.g.: aspirin, clopidogrel (bolivu), abciximab, prostacyclin, prostaglandin E1, etc. ], lipid-regulating drugs such as statins and ACEI/ARBs, with additions or non-additions being prohibited during the observation period.
In the observation process, if the condition of the patient is aggravated and other medicines which violate the test scheme need to be taken, the patient should be quitted by stopping the medicine immediately, and the patient receives the treatment by the clinical routine method, and the detailed record and description of the condition when stopping the medicine are taken as the endpoint treatment evaluation of the study and used for analyzing the report; the medicine or other treatments which are needed to be continuously taken for the combined diseases need to be recorded in the study medical record, such as medicine name (or other treatment name), dosage, use times, time and the like, and the record of dosage change at each stage of the treatment course is paid attention to so as to be analyzed and reported in the process of summarizing; after the clinical test is finished, the patients who are not cured are treated according to the current clinical routine method.
3. Standard of therapeutic effect
Refer to the clinical guidelines of treating coronary heart disease and angina pectoris with new Chinese medicines.
3.1 the curative effect judgment standard of angina pectoris, according to the change of angina pectoris score:
the method has the following advantages: the symptoms of angina pectoris disappear or basically disappear, and the total score of angina pectoris is reduced by more than or equal to 70 percent;
secondly, the method is effective: the frequency, degree and duration of pain attack are obviously reduced, and the grade of angina pectoris is reduced by more than or equal to 30%;
③ invalid: the symptoms of angina pectoris are not improved basically, and the score of the symptoms of angina pectoris is reduced by less than 30 percent;
weighting: the symptoms of angina pectoris are aggravated, namely the total symptom score of the angina pectoris is reduced to less than 0.
3.2 angina pectoris disappearance rate judgment standard:
firstly, disappearance: the frequency of angina attack (times/week) is more than 0 before administration and 0 after administration;
② does not disappear: the frequency of angina attack (times/week) is greater than 0 before administration and is not 0 after administration.
3.3 therapeutic effect judgment standard of electrocardiogram change:
the method has the following advantages: the electrocardiogram is restored to "approximately normal" (i.e., "normal range") or to "normal electrocardiogram";
secondly, the method is effective: reduction of the S-T segment to increase back above 0.05mV after treatment, but not to normal levels, with shallower T-wave changes (above 25%) in the major lead inversion: or T-wave changes from flat to upright, and atrioventricular or intraventricular conduction block improves;
③ invalid: the electrocardiogram is basically the same as before treatment;
weighting: the S-T segment is reduced by more than 0.05mV before treatment, the T wave deepens (more than 25 percent) or the vertical T wave flattens in the main lead inversion, the flat T wave becomes inverted, and ectopic heart rhythm, atrioventricular block or intraventricular block appears.
3.4 the judgment standard of the syndrome curative effect is judged according to the integral change of the syndrome:
the method has the following advantages: the traditional Chinese medicine syndrome integral is reduced by more than or equal to 70 percent;
secondly, the method is effective: the traditional Chinese medicine syndrome integral is reduced by more than or equal to 30 percent and less than 70 percent;
③ invalid: clinical symptoms and physical signs are not obviously improved, and the syndrome integral is reduced by less than 30 percent;
weighting: the clinical symptoms and physical signs are aggravated, and the integral reduction of the syndrome is less than 0.
3.5 nitroglycerin stop-decreasing rate:
stopping medicine: stopping taking the medicine completely after treatment;
reducing weight: the dosage of the drug after treatment is reduced by more than 50 percent compared with that before treatment;
③ unchanged: the dosage of the medicine is reduced by less than 50 percent after treatment;
fourthly, unused: nitroglycerin tablets were not used before and after treatment.
4. Statistical method
Adopting SAS 9.2 software for analysis; all statistical tests used a two-sided test, and P values less than or equal to 0.05 would be considered statistically significant for the differences tested.
Analyzing a data set
4.1 complete analysis set (FAS): refer to the collection of qualified and shed cases, but not to knockout cases. When the main efficacy index is missing, the previous result is used for transfer according to the Intention To Treat (ITT) analysis. The comparative analysis and the missing value of the secondary efficacy index are not carried out (data-carry-forward), and the analysis is carried out according to the actually obtained data.
4.2 compliance with the protocol set (PPS): refers to the collection of cases meeting the inclusion criteria and the exclusion criteria and completing the treatment plan, i.e. the analysis (PP analysis) is performed on the cases meeting the test plan, having good compliance and completing the filling content of CRF regulations.
4.3 safety data set (SS): at least one treatment is received, and the actual data recorded by the safety index exist. The security missing value cannot be carried forward; partial knockout cases that can be evaluated are included, such as cases with an age above inclusion criteria, but not including cases where the use of drugs for contraindication results in an inability to make a safety judgment. The incidence of adverse reactions was denominated in the number of cases in the safety set.
5. Test results
5.1 curative effects on angina pectoris
TABLE 1 comprehensive analysis of the curative effects of multicentric angina pectoris (4wk) (PPS)
Deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo grade, Q is 26.841, P is 0.000
Significant efficiency, subtraction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 9.519, P is 0.002
Total effective rate, deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 26.729, P is 0.000
TABLE 2 Combined assay of the efficacy of multicenter angina pectoris (4wk) (FAS)
Deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo grade, Q is 30.829, P is 0.000
Significant efficiency, subtraction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 9.451, P is 0.002
Total effective rate, deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 31.812, P is 0.000
The results shown in tables 1-2 show that: compared with placebo control group, Huatuo Zaizao pill has significant statistical significance on angina pectoris comprehensive curative effect, significant efficiency and total effective rate of patients with stable fatigue type angina pectoris, P is less than 0.01, and PP analysis is consistent with FAS. The Huatuo Zaizao pills have definite therapeutic significance for treating the angina attack of patients with stable fatigue type angina.
5.2 angina pectoris composite score analysis
TABLE 3 measured values of angina pectoris score with time (comparison between groups and analysis before and after group) (PPS)
TABLE 4 measured values of angina pectoris score change with time (comparison between groups and analysis before and after group) (FAS)
TABLE 5 duration of change of angina pectoris score from baseline difference (posterior-anterior) (PPS)
TABLE 6 duration of change of angina score from baseline difference (post-pre) (FAS)
As shown in tables 3-6, after 2 weeks and 4 weeks of treatment, angina pectoris scores of the Huatuo Zaizao pill test group and the placebo control group are all significantly reduced (P <0.05), compared with the two groups, the difference is not significant (P >0.05) after 2 weeks, the difference has significant statistical significance (P <0.01) after 4 weeks, and the Huatuo Zaizao pill has exact treatment significance on angina pectoris attack conditions of patients with the stability fatigue type angina pectoris after 4 weeks of treatment. FAS is consistent with PP.
5.3 analysis of the number of angina pectoris attacks
TABLE 7 duration of change of number of seizures (times/week) from baseline difference (post-pre) (PPS)
TABLE 8 duration of change in number of seizures (beats/week) from baseline difference (post-pre) (FAS)
TABLE 9 number of episodes (times/week) observed changes with time (comparison between groups and analysis before and after group) (PPS)
TABLE 10 number of episodes (times/week) observed values varied with time (comparison between groups and analysis before and after group) (FAS)
As shown in tables 7-10, after 2 weeks and 4 weeks of treatment, angina pectoris attack times of the Huatuo Zaizao pill test group and the placebo control group are significantly reduced (P <0.05), compared with the two groups, the difference is not significant (P >0.05) after 2 weeks, the difference has significant statistical significance (P <0.01) after 4 weeks, and the Huatuo Zaizao pill has exact treatment significance on angina pectoris attack times of patients with stable overwork type angina after 4 weeks of treatment. FAS is consistent with PP.
5.4 angina pectoris duration (min/min) analysis
TABLE 11 duration (min/min) change with time from baseline (post-pre) (PPS)
TABLE 12 duration (min/min) change with time from baseline difference (post-pre) (FAS)
TABLE 13 duration (min/min) measured changes with time (comparison between groups and analysis before and after group) (PPS)
TABLE 14 duration (min/min) measured values over time (comparison between groups and analysis before and after group) (FAS)
As shown in tables 11-14, after 2 weeks and 4 weeks of treatment, angina pectoris attack duration time is significantly reduced (P <0.05) in Huatuo Zaizao pill test group and placebo control group, compared with the two groups, difference is not significant (P >0.05) after 2 weeks, difference is significant (P <0.01) after 4 weeks, which indicates that Huatuo Zaizao pill has exact treatment significance for angina pectoris attack duration time of patients with stable exertional angina pectoris after 4 weeks of treatment. FAS is consistent with PP.
5.2 Electrocardiogram efficacy analysis
TABLE 15 comprehensive analysis of the curative effects of multicenter electrocardiogram (4wk) (PPS)
Deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo grade, Q is 8.670, P is 0.003
Significant efficiency, subtraction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 3.262, P is 0.071
Total effective rate, deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 7.217, P is 0.007
TABLE 16 comprehensive analysis of the curative effects of multicenter electrocardiography (4wk) (FAS)
Deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo grade, Q is 7.842, P is 0.005
Significant efficiency, subtraction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 3.138, P is 0.077
Total effective rate, deduction of intercentral variation, CMH χ 2 test: the Huatuo Zaizao pill is compared with placebo comprehensively, Q is 6.252, P is 0.012
As shown in tables 15-16, the results of clinical trials of Huatuo Zaizao pills for treating coronary heart disease and angina pectoris (phlegm stagnation syndrome) show that: compared with placebo control group, Huatuo Zaizao pill has statistical significance in improving electrocardiogram curative effect on patients with stable fatigue type angina (phlegm stagnation syndrome), P is less than 0.05, and PP analysis is consistent with FAS. The Huatuo Zaizao pill has therapeutic significance for treating the electrocardiogram of patients with stable fatigue type angina pectoris.
5.3 Glycerol nitrate reduction Rate
TABLE 17 Glycerol nitrate Rate of Change analysis (4wk) (PPS)
Discontinuation rate, deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 0.052, P is 0.820
Withdrawal rate, deduction of intercentral variation, CMH χ 2 test: when Huatuo reproduced pill is compared with placebo comprehensively, Q is 3.125, P is 0.077
TABLE 18 Glycerol nitrate Rate of Change analysis (4wk) (FAS)
Discontinuation rate, deduction of intercentral variation, CMH χ 2 test: comparing Huatuo Zaizao pill with placebo, Q is 0.375, P is 0.540
Withdrawal rate, deduction of intercentral variation, CMH χ 2 test: the Huatuo Zaizao pill is compared with placebo comprehensively, Q is 4.336, P is 0.037
Note: 1. the withdrawal rate is 100% of withdrawal/total cases; 2. the withdrawal rate is (withdrawal + decrement)/total count 100%; 3. analysis of Only cases Using nitroglycerin
As shown in tables 17-18, the Huatuo Zaizao pill group and placebo control group had a part of the nitroglycerin tablets that were not used after 4 weeks of administration, while the Huatuo Zaizao pill group had a reduced dose of nitroglycerin tablets for all patients after administration. Compared to the placebo control group, FAS analysis showed that nitroglycerin withdrawal rate was statistically different from the placebo control group (P < 0.05).
In conclusion, the invention discovers that the Huatuo Zaizao pills have obvious comprehensive curative effect on angina pectoris of patients, can obviously reduce angina pectoris scores of the patients, can obviously reduce angina pectoris attack times of the patients, can obviously reduce angina pectoris attack duration of the patients, can improve electrocardiogram of the patients, and can reduce usage of nitroglycerin tablets by the patients. The research result of the invention provides scientific basis for the application of Huatuo Zaizao pills in treating angina pectoris with fatigue stability.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (7)
1. Application of HUATUOZAIZAO pill in preparing medicine for treating angina pectoris due to fatigue is provided.
2. The use according to claim 1, wherein the treatment is of a significant combined effect on angina pectoris in the patient.
3. The use according to claim 1, wherein the treatment is a significant reduction in the patient's angina score.
4. The use according to claim 1, wherein the treatment is a significant reduction in the number of angina attacks in the patient.
5. The use according to claim 1, characterized in that the treatment is a significant reduction in the duration of an angina attack in a patient.
6. Use according to claim 1, characterized in that the treatment is an improvement of the electrocardiogram of the patient.
7. Use according to claim 1, wherein the treatment is a reduction of the patient's use of nitroglycerin tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011165895.6A CN112168887A (en) | 2020-10-27 | 2020-10-27 | Application of Huatuo Zaizao pill in preparing medicine for treating stable fatigue type angina pectoris |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011165895.6A CN112168887A (en) | 2020-10-27 | 2020-10-27 | Application of Huatuo Zaizao pill in preparing medicine for treating stable fatigue type angina pectoris |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112168887A true CN112168887A (en) | 2021-01-05 |
Family
ID=73922309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011165895.6A Pending CN112168887A (en) | 2020-10-27 | 2020-10-27 | Application of Huatuo Zaizao pill in preparing medicine for treating stable fatigue type angina pectoris |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112168887A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023173581A1 (en) * | 2022-03-18 | 2023-09-21 | 广州白云山奇星药业有限公司 | New use of huatuo zaizao pill |
-
2020
- 2020-10-27 CN CN202011165895.6A patent/CN112168887A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 刘克英等: "华佗再造丸治疗冠状动脉粥样硬化性心脏病心绞痛疗效观察", 《中药材》 * |
| 方素钦等: "华佗再造丸治疗冠心病心绞痛63例临床观察", 《福建中医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023173581A1 (en) * | 2022-03-18 | 2023-09-21 | 广州白云山奇星药业有限公司 | New use of huatuo zaizao pill |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moir et al. | Cardiotoxicity of amitriptyline | |
| Ahlmark et al. | Long-term treatment with β-blockers after myocardial infarction | |
| Théroux et al. | A randomized study comparing propranolol and diltiazem in the treatment of unstable angina | |
| Monstad et al. | Preemptive oral treatment with sumatriptan during a cluster period | |
| Israeli SPRINT Study Group | Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction | |
| Zou et al. | Evaluation of the traditional Chinese Medicine Shensongyangxin capsule on treating premature ventricular contractions: a randomized, double-blind, controlled multicenter trial | |
| Meinertz et al. | Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study) | |
| Amsterdam et al. | Evaluation of long-term use of propranolol in angina pectoris | |
| Davison et al. | Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial | |
| Yamashita et al. | Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study) | |
| Kaufman et al. | Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma | |
| CN112168887A (en) | Application of Huatuo Zaizao pill in preparing medicine for treating stable fatigue type angina pectoris | |
| Trippel et al. | Atenolol in children with ventricular arrhythmias | |
| Miller et al. | The action of procaine amide in cardiac arrhythmias | |
| Ceremużyński et al. | Ventricular arrhythmias late after myocardial infarction are related to hypomagnesemia and magnesium loss: preliminary trial of corrective therapy | |
| Qiong et al. | Clinical non-inferiority trial on treatment of coronary heart disease angina pectoris of Xin-blood stasis syndrome type with lyophilized Salvia salt of lithospermic acid powder for injection | |
| Grenadier et al. | The efficacy of ajmaline in ventricular arrhythmias after failure of lidocaine therapy in the acute phase of myocardial infarction | |
| Atarashi et al. | Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation | |
| CN111840459B (en) | Astragalus root and five-ginseng traditional Chinese medicine composition and application thereof | |
| Bakavoli et al. | Cardiac arrhythmia due to ledipasvir/sofosbuvir iranian counterpart, commercially named as Ledibiox: A case report. | |
| Bendtzen | Are Microbiomes Involved in Paroxysmal Atrial Fibrillation? Repeated Clinical Improvement after Pivmecillinam (Amdinocillin) Therapy | |
| Taylor et al. | Safety and effectiveness of ibutilide in a community hospital | |
| Stroobandt et al. | Intravenous metoprolol for the treatment of acute supraventricular tachyarrhythmias | |
| Iga et al. | Problems in Pharmacological Evaluation of Patients with Paroxysmal A trial Fibrillation: Clinical Analysis of More Than 100 Consecutive Patients | |
| Al Harbi et al. | A case of granisetron associated intraoperative cardiac arrest |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210105 |